Cardlytics, Inc. August 13, 2024 Join Investigation Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox & Kilsheimer LLP is Investigating Cardlytics, Inc. (CDLX) for Potential Securities Law Violations Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Cardlytics, Inc. (CDLX) (“Cardlytics” or the “Company”) (NASDAQ: CDLX). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Cardlytics investor and have suffered losses, you may click here to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On August 7, 2024, Cardlytics announced its financial results for the second quarter of 2024, disclosing second quarter revenue of $69.6 million, a 9% year-over-year revenue decline, which missed its prior guidance expectation of revenue between $73 million and $81 million. During the conference call to discuss second quarter results, the Company attributed its Q2 revenue miss to “delivery issues.” The Company also announced that Karim Temsamani, the Chief Executive Officer and member of the Board of Directors, will be stepping down from both roles effective August 16, 2024. Following this news, the price of Cardlytics stock price fell $3.94 per share, over 57%, to close at $2.96 per share on August 8, 2024. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003E-mail: pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704Fax: (415) 772-4707E-mail: lking@kaplanfox.com Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Quanterix Corp See the Case MediaAlpha, Inc. See the Case PACS Group, Inc. See the Case WM Technology See the Case Humacyte, Inc. See the Case Acadia Healthcare Company, Inc. See the Case Edwards Lifesciences Corporation See the Case United Parcel Service, Inc. See the Case Elanco Animal Health Incorporated See the Case Iris Energy Ltd See the Case Toronto-Dominion Bank See the Case Fluence Energy, Inc. See the Case
